The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to deepen collaboration with the US on medical technology regulation, with initiatives to accelerate innovation, strengthen patient safety, and reduce transatlantic barriers to market access.  

Speaking at the Advanced Medical Technology Association (AdvaMed) conference in San Diego, MHRA Chief Executive Lawrence Tallon outlined the Agency's commitment to advancing global regulatory harmonisation.

He highlighted that the UK's medtech regulatory reforms  will support earlier and safer patient access to innovative technologies.

He said: "We continue to work in close collaboration, and are taking steps forward in the relationship between FDA and MHRA to strengthen regulatory alignment and reciprocity.  We share an ambition to accelerate joint initiatives, enhance policy development, and identify and work together on strategic opportunities more effectively."

A new  National Commission on the Regulation of AI in Healthcare has been launched, which brings together leading voices from across the UK and internationally. It will work to shape recommendations on regulating AI-driven medical technologies, contributing to international alignment and accelerating safe access to AI in healthcare and across the NHS.